4-(3-Hydroxypropyl)thiomorpholine 1,1-Dioxide → N-[7-[3-(1,1-dioxo-1,4-thiazinan-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyridine-3-carboxamide

Participants

Reaction Steps

The procedure used for the preparation of Example 4 was used to prepare the title compound from N-(7-hydroxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide (Intermediate C) and 3-(1,1-dioxidothiomorpholin-4-yl)propan-1-ol. High vacuum drying at 60° C. gave the title compound (105 mg, 45%): HPLC MS RT=1.16 min, MH+=483.2; 1H NMR (DMSO-d6+2 drops TFA-d) δ: 2.32-2.33 (2H, m), 3.53-3.58 (2H, m), 3.66 (4H, bs), 3.87 (4H, bs), 4.27-4.40 (2H, m), 4.58-4.65 (2H, m), 7.60 (1H, t), 7.70 (1H, d), 7.93 (1H, dd), 8.89 (1H, d), 8.99 (1H, dd), 9.50 (1H, s).

Provenance & Evidence